224 related articles for article (PubMed ID: 26372833)
1. Severe rash associated with vemurafenib administration following nivolumab therapy.
Imafuku K; Yoshino K; Ishiwata K; Otobe S; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e84-e86. PubMed ID: 26372833
[No Abstract] [Full Text] [Related]
2. Vemurafenib sensitivity skin reaction after ipilimumab.
Harding JJ; Pulitzer M; Chapman PB
N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
[No Abstract] [Full Text] [Related]
3. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Johnson DB; Wallender EK; Cohen DN; Likhari SS; Zwerner JP; Powers JG; Shinn L; Kelley MC; Joseph RW; Sosman JA
Cancer Immunol Res; 2013 Dec; 1(6):373-7. PubMed ID: 24490176
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo.
Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Kiyota N; Ejima Y; Nakajima K; Nishigori C
Eur J Dermatol; 2017 Apr; 27(2):177-178. PubMed ID: 27873735
[No Abstract] [Full Text] [Related]
5. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
Devic P; Amini-Adle M; Camdessanché JP; Dalle S
Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
[No Abstract] [Full Text] [Related]
6. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
7. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Tsuboi S; Yoshino K; Yamaguchi K; Imafuku K; Ohara K
J Dermatol; 2017 May; 44(5):607-608. PubMed ID: 27334634
[No Abstract] [Full Text] [Related]
8. Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.
Ludlow SP; Pasikhova Y
Melanoma Res; 2013 Dec; 23(6):496-7. PubMed ID: 24025700
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
10. Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
Sondermann W; Griewank KG; Schilling B; Livingstone E; Leyh JC; Rompoti N; Cosgarea I; Schimming T; Schadendorf D; Zimmer L; Hillen U
PLoS One; 2015; 10(4):e0124590. PubMed ID: 25897843
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib-induced bilateral facial palsy.
Shailesh FN; Singh M; Tiwari U; Hutchins LF
J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
[TBL] [Abstract][Full Text] [Related]
13. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
14. Nonmalignant cutaneous findings associated with vemurafenib.
Sukhnandan F; Kahn MR; Bhattacharjee P
Cutis; 2018 Jan; 101(1):E2-E4. PubMed ID: 29529120
[No Abstract] [Full Text] [Related]
15. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.
Anforth R; Carlos G; Eiris N; Clements A; Fernandez-Peñas P
Med J Aust; 2015 Jul; 203(1):41-2. PubMed ID: 26126567
[No Abstract] [Full Text] [Related]
16. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy for metastatic melanoma in 2012: dawn of a new era.
Bhatia S; Thompson JA
J Natl Compr Canc Netw; 2012 Mar; 10(3):403-12. PubMed ID: 22393198
[TBL] [Abstract][Full Text] [Related]
18. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
[TBL] [Abstract][Full Text] [Related]
19. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
20. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]